Khokon Miah Akanda: FDA Approves a First-in-Class Hypertension Drug
Khokon Miah Akanda, Senior Brand Executive at Apex Pharma Limited, shared on LinkedIn:
“FDA approves a first-in-class hypertension drug!
The US FDA has recently approved Baxfendy (baxdrostat) by AstraZeneca, the first-ever aldosterone synthase inhibitor for hypertension treatment.
What makes this approval significant is its completely new mechanism of action. Instead of only managing symptoms, the drug directly targets aldosterone production, a hormone linked to persistently high blood pressure and cardiovascular risk.
In Phase III trials, the drug demonstrated clinically meaningful reductions in systolic blood pressure in patients whose hypertension remained uncontrolled despite multiple medications.
This marks one of the most important cardiovascular drug innovations in recent years and highlights how pharma continues to evolve toward more targeted and mechanism-based therapies.
Exciting to see innovation reshaping chronic disease management.”
Stay updated with Hemostasis Today.
-
Oct 14, 2026, 17:24EHC ERIN Webinar on Fibrinogen Disorders
-
Oct 14, 2026, 16:50Peter Kouides: The Role of Multidisciplinary Networks in Women’s Hematologic Care
-
Oct 14, 2026, 16:35Thaís Leonel: Analytical Consistency as a Foundation for Evidence-Based Thrombosis Management
-
Oct 14, 2026, 16:28Christina Yiangou: Presenting the HemaFAIR Project at ASCAT 2026 in London
-
Oct 14, 2026, 16:27ITP Research and the Importance of Patient Involvement – ITP Australia and New Zealand
-
Oct 14, 2026, 16:19Ganesh Mohan: Complexities of Thrombosis Care Across Diverse Patient Populations
-
Oct 14, 2026, 16:17Louise St. Germain Bannon: Every Conversation Matters Beyond World Thrombosis Day
-
Oct 14, 2026, 16:11Christina Pierre: A Life-Course Approach to Thrombosis Risk in Women
-
Oct 14, 2026, 16:06Belinda Minnaar: Recognizing Leadership in VTE Prevention on World Thrombosis Day